6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
5m ago	Cushman & Wakefield Arranges $74.1 Million Financing for Bank of Italy Office-to-Residential Conversion in Downtown San Jose
12m ago	EVS Broadcast Equipment : announces CFO transition following five years of record growth
14m ago	Duke Energy : Florida completes solar energy site in Sumter County, estimates $250 million in customer savings over its service lifetime
16m ago	Kraft Heinz Announces Pricing Terms and the Accepted Tender Amounts for the Cash Tender Offer for Up To $1.1 Billion Aggregate Purchase Price of Certain of Its Outstanding Notes
16m ago	L.B. Foster Company Announces the Appointment of Executive Officers

About

1.80USD-0.04 -1.91%

Closed • Updated at 18:52 GMT+00:00

Market Cap$79.95M

Volume426.7K

Beta0.72

RSI58.75

Health TechnologyBiotechnology

Os Therapies Incorporated — investor relations, events, news, and company updates on 6ix.

Latest News

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

Community Chat

Ask AI